Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAID BEYDOUN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology

NPI
1700827482
CMS profile
77490
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$203,751.19

175 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $42,155.99 36
Takeda Pharmaceuticals U.S.A., Inc. $39,856.77 37
Alexion Pharmaceuticals, Inc. $38,988.98 33
ARGENX US, INC. $30,813.98 27
AstraZeneca Pharmaceuticals LP $18,163.31 11
Alnylam Pharmaceuticals Inc. $9,336.27 9
Amgen Inc. $8,976.31 7
CSL Behring $5,185.00 3
Janssen Global Services, LLC $4,744.07 4
Grifols USA, LLC $2,298.53 3
Janssen Scientific Affairs, LLC $1,090.00 1
Amylyx Pharmaceuticals, Inc. $1,050.00 2
Octapharma USA, Inc. $1,000.00 1
GENZYME CORPORATION $91.98 1

Page 2 of 4; records 51–100 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAID BEYDOUN

NPI 1700827482 · CMS profile ID 77490

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Clinical Neurophysiology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700827482?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAID BEYDOUN, NPI 1700827482, CMS profile ID 77490. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700827482?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SAID BEYDOUN, NPI 1700827482, CMS profile ID 77490. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700827482?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SAID BEYDOUN, NPI 1700827482, CMS profile ID 77490, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1700827482?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

175 matching records · $203,751.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 175 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 175.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $58.7608/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142115343 CMS
ARGENX US, INC. $7.7708/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142115369 CMS
ARGENX US, INC. $125.0008/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142113943 CMS
ARGENX US, INC. $1,250.0008/01/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155404314 CMS
AstraZeneca Pharmaceuticals LP $2,150.0007/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104572114 CMS
Takeda Pharmaceuticals U.S.A., Inc. $238.2607/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487621 CMS
Takeda Pharmaceuticals U.S.A., Inc. $608.2107/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487625 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.9907/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487628 CMS
Takeda Pharmaceuticals U.S.A., Inc. $50.0007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487632 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.0607/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487636 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.0007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487640 CMS
Takeda Pharmaceuticals U.S.A., Inc. $246.1607/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487614 CMS
Takeda Pharmaceuticals U.S.A., Inc. $124.9907/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487617 CMS
AstraZeneca Pharmaceuticals LP $70.6407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105682339 CMS
Alnylam Pharmaceuticals Inc. $974.6107/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125831991 CMS
Alnylam Pharmaceuticals Inc. $118.0207/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125831993 CMS
ARGENX US, INC. $3,750.0007/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142113567 CMS
AstraZeneca Pharmaceuticals LP $1,050.0007/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104211461 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.8207/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487602 CMS
Takeda Pharmaceuticals U.S.A., Inc. $742.4207/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487606 CMS
Takeda Pharmaceuticals U.S.A., Inc. $267.3207/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487610 CMS
ARGENX US, INC. $204.0607/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142115205 CMS
ARGENX US, INC. $541.9507/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142115421 CMS
ARGENX US, INC. $43.2207/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142115793 CMS
Alnylam Pharmaceuticals Inc. $116.5507/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125831987 CMS
ARGENX US, INC. $1,250.0007/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142113311 CMS
UCB, Inc. $1,300.0007/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143349603 CMS
ARGENX US, INC. $109.3606/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142113597 CMS
UCB, Inc. $1,300.0006/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143349598 CMS
Alexion Pharmaceuticals, Inc. $2,950.0006/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093923553 CMS
Alexion Pharmaceuticals, Inc. $119.8306/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093925979 CMS
ARGENX US, INC. $60.0006/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142114621 CMS
ARGENX US, INC. $674.7306/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142114625 CMS
AstraZeneca Pharmaceuticals LP $3,200.0005/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105606871 CMS
AstraZeneca Pharmaceuticals LP $1,162.2905/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105499894 CMS
AstraZeneca Pharmaceuticals LP $123.3805/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105722923 CMS
ARGENX US, INC. $46.9805/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142114333 CMS
ARGENX US, INC. $110.0005/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142114983 CMS
ARGENX US, INC. $22.6805/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142114999 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7,118.5005/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487598 CMS
UCB, Inc. $640.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143349585 CMS
UCB, Inc. $640.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143349589 CMS
UCB, Inc. $1,280.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143349594 CMS
Amgen Inc. $32.7805/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115449294 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.0005/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487591 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.1205/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137487595 CMS
ARGENX US, INC. $2,812.5005/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142114325 CMS
Alexion Pharmaceuticals, Inc. $721.7205/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093977230 CMS
Alexion Pharmaceuticals, Inc. $121.7205/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093985846 CMS
Alexion Pharmaceuticals, Inc. $214.9205/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093990119 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $166,803.95 185
PY2020 $91,614.10 67
PY2021 $57,535.13 52
PY2022 $118,158.88 97
PY2023 $161,380.25 154
PY2024 $203,751.19 175
PY2025 $186,245.93 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $225,481.06 24
PY2024 Principal investigator $148,553.41 85
PY2023 Principal investigator $341,284.78 49
PY2022 Recipient $780.00 1
PY2022 Principal investigator $191,334.64 29
PY2021 Recipient $3,200.00 1
PY2021 Principal investigator $250,284.72 35
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $150,545.70 19
PY2019 Principal investigator $165,036.43 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 10/27/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226142860
Principal investigator 1 SANOFI US SERVICES INC. $2,950.00 10/06/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226142849
Principal investigator 1 Novartis Pharmaceuticals Corporation $301.12 10/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190306749
Principal investigator 1 SANOFI US SERVICES INC. $1,850.00 06/23/2025 Non-covered Recipient Entity
University Of Southern California
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226140241
Principal investigator 1 SANOFI US SERVICES INC. $2,150.00 06/23/2025 Non-covered Recipient Entity
University Of Southern California
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226140245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184207969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184208095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,986.53 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200263
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 05/27/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226142795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194045
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,616.68 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190304501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $891.81 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184190147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,726.51 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184190149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,867.40 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184176834
Principal investigator 1 SANOFI US SERVICES INC. $8,450.00 03/17/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226142694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,783.62 02/17/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154130
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,599.45 01/31/2025 Non-covered Recipient Entity
KECK SCHOOL OF MEDICINE
A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) No dispute reported 06/30/2026 1190307925
Principal investigator 1 SANOFI US SERVICES INC. $11,050.00 01/21/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226142698
Principal investigator 1 UCB SA $7,964.38 01/15/2025 Non-covered Recipient Entity
University Of Southern California
Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1246657278
Principal investigator 1 Novartis Pharmaceuticals Corporation $132,693.56 01/01/2025 Non-covered Recipient Entity
KECK SCHOOL OF MEDICINE
A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) No dispute reported 06/30/2026 1190307927